- Home
- ZNTL
as 08-01-2025 4:00pm EST
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.
Upcoming Earnings Alert:
Get ready for potential market movements as Zentalis Pharmaceuticals Inc. ZNTL prepares to release earnings report on 08 Aug 2025.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 105.8M | IPO Year: | 2020 |
| Target Price: | $8.60 | AVG Volume (30 days): | 772.3K |
| Analyst Decision: | Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.15 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.01 - $5.44 | Next Earning Date: | 08-08-2025 |
| Revenue: | $26,865,000 | Revenue Growth: | -33.77% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Zentalis Pharmaceuticals Inc. News
ZNTL Breaking Stock News: Dive into ZNTL Ticker-Specific Updates for Smart Investing
Simply Wall St.
a month ago
Here's Why We're Watching Zentalis Pharmaceuticals' (NASDAQ:ZNTL) Cash Burn Situation
GlobeNewswire
2 months ago
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Simply Wall St.
3 months ago
Zentalis Pharmaceuticals First Quarter 2025 Earnings: US$0.67 loss per share (vs US$0.14 profit in 1Q 2024)
GlobeNewswire
3 months ago
Zentalis Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Progress
GlobeNewswire
3 months ago
Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Simply Wall St.
3 months ago
Pleasing Signs As A Number Of Insiders Buy Zentalis Pharmaceuticals Stock
MT Newswires
3 months ago
Zentalis Pharmaceuticals Doses 1st Patient in Part 2 of Ovarian Cancer Clinical Trial
GlobeNewswire
3 months ago
Zentalis Pharmaceuticals Announces First Patient Dosed in DENALI Part 2 Clinical Trial of Azenosertib in Patients with Cyclin E1+ PROC
Compare ZNTL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ZNTL Zentalis Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.